Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages

被引:144
作者
Lin, Elaine Y. [2 ]
Li, Jiu-feng [1 ]
Bricard, Gabriel [3 ]
Wang, Weigang [4 ]
Deng, Yan [5 ]
Sellers, Rani [6 ]
Porcelli, Steven A. [3 ]
Pollard, Jeffrey W. [1 ]
机构
[1] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Ctr Reprod Biol & Womens Hlth, Dept Dev & Mol Biol, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Div Oncol, Dept Med, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[4] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA
[5] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Analyt & Imaging Facil, Bronx, NY 10461 USA
[6] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA
来源
MOLECULAR ONCOLOGY | 2007年 / 1卷 / 03期
关键词
Vascular endothelial growth factor; Macrophages; Mammary; Tumor; Angiogenesis; Malignancy; Mouse; PyMT; Progression; Transgenic;
D O I
10.1016/j.molonc.2007.10.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic depletion of macrophages in Polyoma Middle T oncoprotein (PyMT)-induced mammary tumors in mice delayed the angiogenic switch and the progression to malignancy. To determine whether vascular endothelial growth factor A (VEGF-A) produced by tumor-associated macrophages regulated the onset of the angiogenic switch, a genetic approach was used to restore expression of VEGF-A into tumors at the benign stages. This stimulated formation of a high-density vessel network and in macrophage-depleted mice, was followed by accelerated tumor progression. The expression of VEGF-A led to a massive infiltration into the tumor of leukocytes that were mostly macrophages. This study suggests that macrophage-produced VEGF regulates malignant progression through stimulating tumor angiogenesis, leukocytic infiltration and tumor cell invasion. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:288 / 302
页数:15
相关论文
共 41 条
[1]   Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 [J].
Barleon, B ;
Sozzani, S ;
Zhou, D ;
Weich, HA ;
Mantovani, A ;
Marme, D .
BLOOD, 1996, 87 (08) :3336-3343
[2]   Angiogenic role of LYVE-1-positive macrophages in adipose tissue [J].
Cho, Chung-Hyun ;
Koh, Young Jun ;
Han, Jinah ;
Sung, Hoon-Ki ;
Lee, Hyuek Jong ;
Morisada, Tohru ;
Schwendener, Reto A. ;
Brekken, Rolf A. ;
Kang, Guson ;
Oike, Yuichi ;
Choi, Tae-Saeng ;
Suda, Toshio ;
Yoo, Ook-Joon ;
Koh, Gou Young .
CIRCULATION RESEARCH, 2007, 100 (04) :E47-E57
[3]  
de Felipe Pablo, 2004, Genet Vaccines Ther, V2, P13, DOI 10.1186/1479-0556-2-13
[4]   VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis [J].
Dong, JY ;
Grunstein, J ;
Tejada, M ;
Peale, F ;
Frantz, G ;
Liang, WC ;
Bai, W ;
Yu, LL ;
Kowalski, J ;
Liang, XH ;
Fuh, G ;
Gerber, HP ;
Ferrara, N .
EMBO JOURNAL, 2004, 23 (14) :2800-2810
[5]   The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences [J].
Donnelly, MLL ;
Hughes, LE ;
Luke, G ;
Mendoza, H ;
ten Dam, E ;
Gani, D ;
Ryan, MD .
JOURNAL OF GENERAL VIROLOGY, 2001, 82 :1027-1041
[6]   Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy [J].
Dvorak, HF .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4368-4380
[7]   M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes [J].
Eubank, TD ;
Galloway, M ;
Montague, CM ;
Waldman, WJ ;
Marsh, CB .
JOURNAL OF IMMUNOLOGY, 2003, 171 (05) :2637-2643
[8]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[9]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[10]   Role of angiogenesis in tumor growth and metastasis [J].
Folkman, J .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :15-18